Zhitong Hong Kong stocks have long known | Lithium iron phosphate ushered in a wave of price increases Tesla (TSLA.US) hit a new high in nearly a year

[Today's headlines]

CNNC overcomes full-chain technology for preparing iodine-131 by irradiating concentrated targets

According to CNNC's official WeChat account, under the efficient coordination of CNNC's isotope production collaboration platform, China's medical isotope autonomy research has once again spread good news. The platform gave full play to the Group's internal collaborative innovation advantages, integrated the Institute of Nuclear Physics and Chemistry, the Nuclear Power Institute, CNNC Qualcomm, and CNNC 272 uranium industry to overcome the entire Iodine-131 industry chain technology by enriching ¹ ³ºTeO₂ targets, and formed a complete environmentally friendly independent industrial chain from iodine-131 prenuclide preparation and reactor irradiation to nuclear drug research and development. In terms of preparing high-abundance and high-purity tellurium-130 isotopes, the Institute of Nuclear Physics and Chemistry has overcome many key technical problems such as isotope separation, oxide synthesis, and purification, and has successfully prepared a ¹ ³ºTeO2 target with an abundance of over 99% and a nuclear grade purity standard. The Institute of Nuclear Physics and Chemistry and CNNC 272 uranium industry prepare tellurium isotope separation media in batches to stably guarantee the supply of raw materials for tellurium isotope separation. This achievement has filled the gap in large-scale preparation of high-purity tellurium isotopes in China, and provides core support for autonomous and controllable high-end nuclear medicine materials in China.

Guo Lili, Secretary General of the China Isotope and Radiation Industry Association, explained that as of 2024, the State Drug Administration approved the marketing of more than 90 radiotherapy devices, with Chinese brands accounting for more than 70%, completely changing the previous situation of reliance on imported equipment. At the same time, research and development of new radiopharmaceuticals has also entered the fast track. More than 200 pipelines have entered the clinical trial stage. Novel nuclides such as -177 and yttrium-90 have become core increments, providing more accurate solutions for tumor treatment. It involves Hong Kong nuclear drugs China Tongpo (01763) and Yuanda Pharmaceutical (00512).

[General outlook]

The three major US stock indices fell, Tesla rose more than 3% to a new high in nearly a year

Overnight, the US stock Dow Jones Industrial Average fell 41.49 points to close at 48416.56 points, or 0.09%; the S&P 500 stock index fell 10.9 points to close at 6816.51 points, or 0.16%; the Nasdaq Composite Index fell 137.76 points to close at 23057.41 points, or 0.59%. Most of the big tech stocks fell, with Broadcom falling more than 5%, Apple, Amazon, and Micron falling more than 1%, Tesla rising more than 3% to a one-year high, and Nvidia rising 0.73%. The automobile manufacturing, precious metals, travel, and diet pills sectors rose, with Toyota and Lilly rising more than 3%, and Amgen, Pfizer, and Roche rising more than 2%.

According to media reports, Nasdaq said it will submit documents to the US Securities and Exchange Commission on Monday to apply for the introduction of near-round-the-clock stock trading, extending the trading time for stocks and exchange-traded products from 16 hours to 23 hours on five trading days a week.

Popular Chinese securities generally fell. The Hang Seng Index ADR declined. On a proportional basis, it closed at 25577.23 points, down 51.65 or 0.20% from the Hong Kong closing.

COMEX gold futures rose by $6.00, or 0.14%, to $4334.3 per ounce for the month. International silver prices rose, and spot silver rose 3.34% to $64.09 per ounce. COMEX silver futures rose 3.42% to $64.130 per ounce.

[Hot Topics Preview]

Lithium iron phosphate ushered in a wave of price increases. Some leading companies have locked orders and expanded production ahead of schedule

Beginning in early December, the new energy industry chain ushered in price fluctuations. Among them, manufacturers of lithium iron phosphate cathode materials set off a wave of collective price increases. Recently, the reporter learned from various sources such as some leading lithium iron phosphate companies, the China Chemical and Physical Power Supply Industry Association, industry analysts, etc., that as 2026 is about to be reached, a number of lithium iron phosphate companies have begun to discuss prices with customers. Some leading companies have put forward requests for price increases, and the increase is concentrated between 2000 and 3000 yuan/ton. Some companies have even said that the price increase trend is expected to continue until the fourth quarter of next year. The reporter discovered that in addition to being driven by demand for energy storage, this round of price increases for lithium iron phosphate are also driven by rising costs of raw materials such as lithium carbonate. Some analysts said that as a key raw material for lithium iron phosphate cathode materials, every 10,000 yuan/ton price increase, it will directly push up the cost of the cathode material by about 2,300 to 2,500 yuan/ton.

Yao Ming Kangde: The completion of the asset sale transaction is expected to generate a net profit of about 960 million yuan after tax

Yao Ming Kangde announced that Shanghai Yaoming Kangde New Pharmaceutical Development Co., Ltd., a wholly-owned subsidiary of the company, has received the initial share transfer price of 1.54 billion yuan from the transferee. The delivery prerequisites agreed in the “Equity Transfer Agreement” have been met, the transaction has been completed, and the target company is no longer included in the scope of the company's consolidated statements. The transaction is expected to generate net profit of about 960 million yuan after tax, accounting for more than 10% of the company's most recent audited net profit to mother.

League of Nations People's Livelihood (01456): Terminate transactions related to the establishment of the China Unicom Smart Fund of 480 million yuan

According to the Guolian People's Livelihood announcement, on August 28, 2025, the company agreed that its wholly-owned subsidiary Guolian Tongbao will invest 480 million yuan to jointly establish the Guolian Tongzhi Fund with its affiliate Guolian Life Insurance. As of the announcement date, none of the partners had actually invested, and the fund had not been formally established or filed. On December 15, Guolian Tongzhi Fund held a partner meeting and decided to dissolve the fund and go through commercial and commercial cancellation procedures. Guolian Tongbao will take the lead in liquidation and deregistration matters. This termination will not adversely affect the company's finances and operations, and there will be no harm to the rights and interests of the company or shareholders.

Vanke A: The guarantee balance of the company and its holding subsidiaries was RMB 84.493 billion, no overdue guarantee matters

Vanke A announced that the company's holding subsidiary has applied for a loan from the bank in the early stages, and the company's holding subsidiary will continue to separately guarantee the corresponding loan through credit guarantees, equity pledges, and asset collateral. As of November 30, 2025, the guarantee balance of the company and its holding subsidiaries was RMB 84.493 billion, accounting for 41.69% of the company's net assets attributed to shareholders of listed companies after audit at the end of 2024. The company has no overdue guarantees. After this guarantee is issued, the total external guarantees of the company and its holding subsidiaries will be 84.493 billion yuan, accounting for 41.69% of the company's net assets audited to shareholders of listed companies at the end of 2024.

Botai Auto Federation (02889) received the first project fixed notice from a leading domestic NEV customer

According to the Zhitong Finance App, Botai Auto Federation (02889) announced that the company recently obtained the first project fixed notice from a leading domestic NEV customer (this customer) to provide a smart cockpit domain controller solution based on a high-end cockpit domain controller project for its next-generation smart models. As of the date of this announcement, this project is the fourth project target for an intelligent cockpit domain controller solution based on a high-end cockpit domain controller project obtained by the Company after listing.

Chenming Paper (01812) plans to sell all shares in the target company for 3.336 billion yuan

Zhitong Finance App News, Chenming Paper (01812) issued an announcement. On December 15, 2025, Zhanjiang Chenming Paper Co., Ltd. (Zhanjiang Chenming Paper, as the seller of the target loan), Hong Kong Chenming (as the seller of the target shares) and the buyer Shouguang Shengjia Investment Co., Ltd. (as the buyer) entered into an equity and loan transfer agreement. Based on this, the company and Hong Kong Chenming agreed to sell the target shares and the target loan at a total cost of RMB 3.336 billion.

The Beijing Haichang Ocean (02255) Park project has fully entered the construction stage

Haichang Ocean Park announced on the Hong Kong Stock Exchange that the Beijing Haichang Ocean Park project has fully entered the construction stage. Currently, several platform foundation construction equipment is in operation. The construction will involve the installation of the thickest acrylic windows in China, anti-seeping work for oversized pools, and integrated installation of various special marine systems; preparations for operation are progressing steadily, and work on performing arts products and exhibition design is also being deepened.

Yihuatong (02402) plans to discount about 14.99% and place up to 8.88 million shares to raise about HK$198 million

Yihuatong (02402) issued an announcement. On December 16, 2025 (before the trading period), the company entered into a placement agreement with the placement agent. According to this, the placement agent has agreed to induce no less than six undertakers to subscribe for up to 8.88 million new H shares according to the terms contained in the placement agreement and subject to its terms and conditions, according to the best effort standards. The placement price of HK$22.68 per H share is approximately 14.99% off of HK$26.68 per share from the closing price of H shares reported on the Stock Exchange on December 15, 2025 (that is, the last trading day and the date of determination of the placement price).

Bijiao Technology's Hong Kong stock IPO and “full circulation” of domestic unlisted shares were registered by the China Securities Regulatory Commission

The International Cooperation Department of the China Securities Regulatory Commission issued a filing notice on the “full circulation” of overseas listed shares and domestic unlisted shares of Shanghai Bijiao Technology Co., Ltd. The company intends to issue no more than 372,458,000 overseas listed common shares and list them on the Hong Kong Stock Exchange. The company's 57 shareholders intend to convert their holdings of a total of 873,272,024 domestic unlisted shares into overseas listed shares and list them for circulation on the Hong Kong Stock Exchange.

IPO: Guoxia Technology (02655) closed up 88.06% in the dark market

AI Internet Energy Storage Leader+AI Robot Safety's No. 1 Stock: Guoxia Technology's dark market closed up 88.06%, earning HK$1,770 per lot. The company focuses on developing and providing energy storage system solutions and products to the company's customers and end users. The company's energy storage system solutions and products are widely used in large-scale power supply side and power grid side, industrial, commercial and home scenarios in the Chinese market and overseas markets.

Tianqi Lithium (09696): Currently, the company's lithium concentrate procurement and transportation arrangements are proceeding normally according to the plan

Some investors asked, Hello Director, does the company's overseas lithium ore equity issue affect overseas mineral imports? Tianqi Lithium said on an interactive platform that the company's current lithium concentrate mainly comes from the Greenbush spodumene mine in Australia controlled by the company. Thalison, a holding subsidiary of the company, is responsible for mining and production. According to the relevant agreement in the “Shareholders' Agreement”, lithium concentrate produced by Thalison is currently only supplied to two shareholders — TLEA and Yabao, the holding subsidiaries of the company. The two shareholders can each obtain about 50% of the actual annual production according to their actual needs. Currently, the company's lithium concentrate procurement and transportation arrangements are proceeding normally according to the plan.

Guangzhou Automobile Group (02238): The flying car GOVY AirCab has entered the airworthiness certification stage and is expected to be mass-produced in 2026

The GAC Group said on an interactive platform that the company's low-altitude travel technology brand, Gaoyu GOVY, has simultaneously laid out a “short-range multi-rotor+cross-city composite wing” product matrix and has released 3 self-developed flying vehicle products, including GOVY AirCar, GOVY AirCab, and GOVY AirJet. The aim is to build an ecosystem covering the entire chain of R&D, production and operation to achieve a new three-dimensional travel method for airspace intermodal transportation. Among them, the multi-rotor GOVY AirCab, which focuses on sightseeing and short-distance leapfrog travel, is the first mass-produced flying vehicle product. It has now entered the airworthiness certification stage, and prototype deliveries have been completed in Beijing and Hong Kong. It is expected that mass production and delivery will be achieved in 2026; the GOVY AirJet flying car, which focuses on intercity travel, will go offline at the end of 2024, and is scheduled to achieve commercial operation in 2028. At the same time, it is actively exploring application scenarios for flying cars in the fields of cultural tourism, emergency rescue, logistics and distribution, etc., and is planning to launch a flying car demonstration operation plan in 2-3 cities in the Guangdong-Hong Kong-Macao Greater Bay Area in 2027 to achieve a “40-minute life cycle in the Guangdong-Hong Kong-Macao Greater Bay Area”.

[Individual stock prices are clear]

China Tongpu (01763): Affiliated Atomic Hi-Tech signs commercial cooperation agreement with Novartis

Zhitong Finance App News, China Tongbo (01763) announced that the Company's subsidiary Atomic Hi-Tech Co., Ltd. (Atom Hi-Tech) and Novartis Pharmaceuticals (Zhejiang) Co., Ltd. (Novartis) have formally signed a commercial cooperation agreement (commercial cooperation agreement) with Pivet® (Lutetium [177Lu] texiverpitide injection). Privitol® is the first and currently the only approved radioligand therapy drug targeting PSMA in China. It is mainly used to treat advanced prostate cancer. In the future, it will provide patients with a new nuclear drug treatment plan to prolong life and improve quality of life. The signing of this agreement opens a strategic cooperation between the two parties on the innovative nuclear drug product Pivitel®. With years of compliance operation experience in the field of radiopharmaceuticals, Atom Hi-Tech will join forces with Novartis to provide customized Pivitel® product supply and solutions to medical institutions and patients to benefit more patients.